Biomedical subjects

H M Deloar

Publications and source records attributed to H M Deloar.

6 recordsLinked to original sources

PubMed2005

Dose calculation system for remotely supporting radiotherapy.

The dose calculation system IMAGINE is being developed keeping in mind remotely supporting external radiation therapy using photon beams. The system is expected to provide an accurate picture of the dose distribution in a patient body, using a Monte Carlo calculation that employs precise models of the patient body and irradiation head. The dose calculation will be performed utilising super-parallel computing at the dose calculation centre, which is equipped with the ITBL computer, and the calculated results will be transferred through a network. The system is intended to support the quality assurance of current, widely carried out radiotherapy and, further, to promote the prevalence of advanced radiotherapy. Prototypes of the modules constituting the system have already been constructed and used to obtain basic data that are necessary in order to decide on the concrete design of the system. The final system will be completed in 2007.

Body Burden↗

PubMed1999

Internal absorbed dose estimation by a TLD method for 18F-FDG and comparison with the dose estimates from whole body PET.

The thermoluminescent dosimeter (TLD) method has been proposed as a useful tool for estimating internal radiation absorbed dose in nuclear medicine. An efficient approach to verify the accuracy of the TLD method has been performed in this study. Under the standard protocol for 2-[F-18]fluoro-2-deoxy-D-glucose (18F-FDG), whole body PET experiments and simultaneous body surface dose measurements by TLDs were performed on six normal volunteers. By using the body surface dose measured with TLDs, the cumulated activities of nine source organs were estimated with a mathematical unfolding technique for three different initial guesses. The accuracy of the results obtained by the TLD method was investigated by comparison with the actual cumulated activity of the same source organs measured by whole body PET. The cumulated activities of the source organs obtained by the TLD method and whole body PET show a significant correlation (correlation coefficient, r > 0.98, level of confidence, p < 0.001) with each other. The mean effective doses in this study are 3.2 x 10(-2) mSv MBq(-1) obtained from the TLD method and 2.9 x 10(-2) mSv MBq(-1) obtained from the whole body PET. Good agreement between the results of the TLD method and whole body PET was observed.

Adult↗

PubMed1998

Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-D-glucose using whole-body positron emission tomography and magnetic resonance imaging.

The purpose of this study was to measure the cumulated activity and absorbed dose in organs after intravenous administration of 2-[F-18]fluoro-2-deoxy-D-glucose (18F-FDG) using whole-body positron emission tomography (PET) and magnetic resonance imaging (MRI). Whole-body dynamic emission scans for 18F-FDG were performed in six normal volunteers after transmission scans. The total activity of a source organ was obtained from the activity concentration of the organ measured by whole-body PET and the volume of that organ measured by whole-body T1-weighted MRI. The cumulated activity of each source organ was calculated from the time-activity curve. Absorbed doses to the individuals were estimated by the MIRD (medical internal radiation dosimetry) method using S-values adjusted to the individuals. Another calculation of cumulated activities and absorbed doses was performed using the organ volumes from the MIRD phantom and the "Japanese reference man" to investigate the discrepancy of actual individual results against the phantom results. The cumulated activities of 18 source organs were calculated, and absorbed doses of 27 target organs estimated. Among the target organs, bladder wall, brain and kidney received the highest doses for the above three sets of organ volumes. Using measured individual organ volumes, the average absorbed doses for those organs were found to be 3.1x10(-1), 3.7x10(-2) and 2.8x10(-2) mGy/MBq, respectively. The mean effective doses in this study for individuals of average body weight (64.5 kg) and the MIRD phantom of 70 kg were the same, i.e. 2.9x10(-2) mSv/MBq, while for the Japanese reference man of 60 kg the effective dose was 2.1x10(-2) mSv/MBq. The results for measured organ volumes derived from MRI were comparable to those obtained for organ volumes from the MIRD phantom. Although this study considered 18F-FDG, combined use of whole-body PET and MRI might be quite effective for improving the accuracy of estimations of the cumulated activity and absorbed dose of positron-labelled radiopharmaceuticals.

Adult↗

PubMed1998

Estimation of internal absorbed dose of L-[methyl-11C]methionine using whole-body positron emission tomography.

L-[Methyl-11C]-methionine (11C-methionine) is proposed as a useful radiotracer for tumour diagnosis. Human biodistribution data of cumulated activities and absorbed doses estimated by the MIRD (medical internal radiation dosimetry) method for 11C-methionine are not available in the literature. In this study we measured the organ activity for 11C-methionine by using whole-body positron emission tomography (PET) and estimated the absorbed doses to 25 organs by the MIRD method. Whole-body dynamic PET scans were performed on five normal volunteers to measure the time course of the organ activity concentration (activity/volume) after intravenous administration of 11C-methionine. Cumulated activities of the ten source organs were calculated from the time-activity curves, obtained from the dynamic PET data. Absorbed dose estimates were performed by the MIRD method for the Caucasian reference man and for the Japanese reference man. The organs which received the highest absorbed doses for the Caucasian reference man were found to be the bladder wall (2.7x10(-2) mGy/MBq), the pancreas (1.9x10(-2) mGy/ MBq), the liver (1.8x10(-2) mGy/MBq) and the kidney (1.1x10(-2) mGy/MBq). The effective doses for the Caucasian reference man and the Japanese reference man were calculated as 5.2x10(-3) and 5.0x10(-3) mSv/MBq, respectively.

Adult↗

PubMed1997

Performance study of a miniature gamma ray scintillation vivo probe for tumor localization.

UNLABELLED: We have developed a miniature gamma-ray endoscopic probe consisting of dual BGO detector probes for tumor detection inside the body cavities. The dual detector system was coupled with random coincidence to decrease the distant background radiation and to improve its spatial resolution for tumor localization. METHOD: The performance of the probe was investigated with a point source and a water phantom. A solution of positron emitting 18F isotope was used as the source. Clinical trials of the probe were done to localize tumors on the skin surface of four subjects carrying tumors close to the body surfaces, into whom 67Ga-citrate and 18F-FDG radiopharmaceuticals were injected. RESULTS: Measurements indicated that the spatial resolution of the dual detector probes is around 1.5 times better than the single detector probe, and both single and dual detector endoscopic probe systems are capable of localizing a tumor on a large photon background. CONCLUSION: The endoscopic probe may be easier to insert inside body cavities due to the small crystal size and the flexible light guides. A single detector probe with higher sensitivity may be useful in searching for tumors over a wide intracavity area but a dual detector probe can be used for precise tumor localization. The detector probe may also be suitable for intraoperative observation.

Adult↗

PubMed1997

Internal dose estimation including the nasal cavity and major airway for continuous inhalation of C15O2, 15O2 and C15O using the thermoluminescent dosimeter method.

UNLABELLED: In the steady state method, 15O-labeled gases (C15O2, 15O2 and C15O) are administered to the body by continuous inhalation in various clinical PET studies. During inhalation, the nasal cavity and major airway may obtain a substantial amount of dose, being the source organs as well as the target organs. The internal absorbed dose to those organs and their contribution to the other target organs have not been calculated by the MIRD method. To calculate the internal dose in the MIRD method, the S values, the absorbed doses per unit of cumulated activities from nasal cavity and major airway to the other organs and vice versa, are needed, and these values are not available. METHODS: In this study, we introduced a mathematical model of the nasal cavity and major airway to calculate their S values to 23 target organs and from 11 source organs to them. Individual experiments were performed to measure the total uptake percentage and body surface doses of 15O-labeled gases from continuous inhalation. RESULTS: Using the body surface doses measured by thermoluminescent dosimeters, the cumulated activities of 11 source organs were estimated with the mathematical transformation method, and then the internal absorbed doses in 23 target organs were calculated by the MIRD method. Our experimental results were compared with the other results, and good agreements were observed. CONCLUSION: Among the target organs, the critical organ is the airway, and the absorbed dose is 2.57 x 10(-2) mGy.MBq-1.

Administration, Inhalation↗